Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Conba Pharmaceutical CoSHSE:600572 +2.61%71 Interest Coverage is 179.72 as of Mar. 2026, which is 1205% above its 10-year median of 13.77. GuruFocus rates SHSE:600572 with a GF Score™ of 71/100 and a GF Value™ of ¥5.51 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 687 Drug Manufacturers companies, Zhejiang Conba Pharmaceutical Co ranks better than 78.31% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zhejiang Conba Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥270 Mil. Zhejiang Conba Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-2 Mil.
Zhejiang Conba Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 179.72.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Zhejiang Conba Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's Interest Coverage or its related term are showing as below:
SHSE:600572'
s Interest Coverage Range Over the Past 10 Years
Min: 5.96 Med: 13.77 Max: 100.03
Current: 100.03
SHSE:600572's Interest Coverage is ranked better than 78.31% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs SHSE:600572: 100.03
Zhejiang Conba Pharmaceutical Co (SHSE:600572) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zhejiang Conba Pharmaceutical Co Interest Coverage Related Terms
Zhejiang Conba Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Zhejiang Conba Pharmaceutical Co Interest Coverage Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Interest Coverage falls into.
Zhejiang Conba Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Interest Coverage of 179.72 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is 1205% above median its historical median of 13.77. Over the past decade, Zhejiang Conba Pharmaceutical Co's Interest Coverage has ranged from 5.96 to 100.03. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #149 out of 687 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Zhejiang Conba Pharmaceutical Co's Interest Coverage too high?
Zhejiang Conba Pharmaceutical Co's current Interest Coverage of 179.72 is 1205% above median its 10-year median of 13.77. Over the past 10 years, this metric has ranged from a low of 5.96 to a high of 100.03. The Drug Manufacturers industry median Interest Coverage is 12.70. Zhejiang Conba Pharmaceutical Co's value of 179.72 is 1315.1% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #149 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #149 out of 687 companies for Interest Coverage. This places Zhejiang Conba Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.70. Zhejiang Conba Pharmaceutical Co's value of 179.72 is 1315.1% above this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own Interest Coverage has ranged from 5.96 to 100.03 over the past decade. While the company's 10-year median is 13.77 vs. the industry median of 12.70, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current Interest Coverage of 179.72 is 1315.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current Interest Coverage is 179.72, which is 1205% above median its own 10-year median of 13.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current Interest Coverage is 179.72, which is 1205% above median its 10-year median of 13.77 and 1315.1% above the Drug Manufacturers industry median of 12.70. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Interest Coverage is 179.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
Interest Coverage: 179.72 (1205% above median its 10-year median of 13.77)
GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
Industry Position: 1315.1% above the Drug Manufacturers median (#149 of 687)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Business Description
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score
Get the complete analysis for SHSE:600572
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
